此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

A Study of Tagmokitug in Combination With Other Treatments in Participants With Advanced or Metastatic Solid Tumors (TREGCHECK 103)

2026年11月13日 更新者:Coherus Oncology, Inc.

A Phase 1/2, Multicenter, Open-Label, Multicohort Study Evaluating the Safety and Efficacy of Tagmokitug in Combination With Other Treatments in Participants With Advanced or Metastatic Solid Tumors

The primary purpose of this study is to evaluate the safety and tolerability of tagmokitug in combination with other therapies.

研究概览

地位

招聘中

条件

研究类型

介入性

注册 (估计的)

12

阶段

  • 阶段2
  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Washington
      • Seattle、Washington、美国、98109
        • 招聘中
        • Fred Hutchinson Cancer Center

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

男性

描述

Key Inclusion Criteria:

  • Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1.
  • Resolved acute effects of any prior therapy to baseline severity or Grade 1 in accordance with National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0, except for adverse events (AEs) not constituting a safety risk per Investigator judgment.

mCRPC:

  • Histologically confirmed adenocarcinoma of the prostate. Adenocarcinoma with focal small cell or neuroendocrine (NE) features based on immunohistochemistry (IHC) alone is permitted. However, small cell carcinoma, carcinoid tumor, mixed NE carcinoma, or large cell NE carcinoma is not permitted.
  • Measurable Castration-resistant Prostate Cancer (mCRPC) as defined by PCWG3 criteria. Participant must have mCRPC that is metastatic either to bone, lymph node (LN), or both without clear evidence of either measurable or nonmeasurable metastasis to visceral organs at the time of screening scan.
  • Participants must have been previously treated with at least 1 prior androgen-receptor pathway inhibitor (ARPI) (ie, abiraterone acetate, enzalutamide, apalutamide, darolutamide).
  • Participants must have received at least one prior taxane therapy unless the participant is ineligible or refused. Participants must not have received other prior cytotoxic chemotherapy (ie, cisplatin, carboplatin, etoposide).
  • Prior orchiectomy or medical castration. Participants who have not undergone orchiectomy, must be receiving ongoing androgen deprivation therapy (ADT) with a gonadotropin-releasing hormone (GnRH) analog with testosterone ≤50 nanogram per deciliter (ng/dL) prior to the first dose of study drug and must continue this therapy throughout the treatment phase.

Key Exclusion Criteria:

  • History of prior malignancy other than the cancer under study that is progressing or has required active treatment within the past 3 years.
  • Prior exposure to anti-CCR8 antibody agents.
  • Prior allogeneic hematological stem cell transplantation or organ transplantation.

mCRPC:

  • Any known prior history of brain metastases of prostate cancer (PCa).
  • Treatment with antineoplastic therapy (including but not limited to cytotoxic chemotherapy, biologic agents, and investigational agents) other than ADT or ARPI within 28 days or <5× the elimination half-life (t½), whichever is earlier, before Day 1.
  • Prior exposure to a T cell engager or human kallikrein 2 (KLK2) targeted therapy.
  • Major surgery requiring general anesthesia within 28 days prior to the first dose of study treatment, still recovering from prior surgery, or with surgery scheduled during the study.

Additional protocol-defined inclusion and exclusion criteria apply.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:mCRPC: Tagmokitug + Pasritamig

Specified dose on specified days.

Specified dose on specified days.

研究衡量的是什么?

主要结果指标

结果测量
大体时间
Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
大体时间:Up to approximately 2.5 years
Up to approximately 2.5 years
Number of Participants with Dose-limiting Toxicities (DLTs)
大体时间:Up to 56 Days
Up to 56 Days

次要结果测量

结果测量
大体时间
客观缓解率 (ORR)
大体时间:最长约 2.5 年
最长约 2.5 年
缓解持续时间 (DOR)
大体时间:最长约 2.5 年
最长约 2.5 年
mCRPC: Prostate Specific Antigen >=50% Response Rate (PSA50) per Prostate Cancer Working Group 3 (PCWG3) Criteria
大体时间:Up to approximately 2.5 years
Up to approximately 2.5 years
Disease Control Rate (DCR)
大体时间:Up to approximately 2.5 years
Up to approximately 2.5 years
mCRPC: Radiographic Progression-free Survival (rPFS)
大体时间:Up to approximately 2.5 years
Up to approximately 2.5 years
Progression-free Survival (rPFS)
大体时间:Up to approximately 2.5 years
Up to approximately 2.5 years
Maximum Observed Serum Concentration of Tagmokitug (Cmax)
大体时间:Up to approximately 2.5 years
Up to approximately 2.5 years
Concentration of Tagmokitug Immediately Before the Next Dose (Ctrough)
大体时间:Up to approximately 2.5 years
Up to approximately 2.5 years
Number of Participants with Anti-drug Antibodies to Tagmokitug
大体时间:Up to approximately 2.5 years
Up to approximately 2.5 years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Study Director、Coherus Oncology

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年11月1日

初级完成 (估计的)

2028年8月1日

研究完成 (估计的)

2028年8月1日

研究注册日期

首次提交

2026年11月13日

首先提交符合 QC 标准的

2026年11月13日

首次发布 (实际的)

2026年11月18日

研究记录更新

最后更新发布 (实际的)

2026年11月18日

上次提交的符合 QC 标准的更新

2026年11月13日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅